Research

Clear Cell Sarcoma has been selected as one of just two ultra-rare cancers for therapeutic development through the ULTRA Program, a new public-private partnership currently in design by the Foundation for the National Institutes of Health (FNIH) in conjunction with NCI, NCATS, and FDA. This milestone means that CCS is now on a national roadmap where the goal is not only to raise awareness, but to design and advance a new treatment. 

Building on promising lab research, our devimistat + hydroxychloroquine CCS trial
(NCT04593758) finished Phase 1 with a safe/tolerable dose. We are now preparing
to launch Phase 2, with enrollment open from age 12+, making this trial accessible to
adolescents as well as adults.

Sponsored by SARC, the Phase II Trial of Tebentafusp is a multi-center, open label study in patients with unresectable or metastatic CCS. Patients who screen positive for HLA-A*02:01 and meet the eligibility requirements will be treated with weekly tebentafusp. This clinical trial began recruiting in November 2025. CCS patients should check eligibility and contact their oncologist for more information.